Validation of a Novel Perceptual Body Image Assessment Method Using Mobile Digital Imaging Analysis: A Cross-Sectional Multicenter Evaluation in a Multiethnic Sample.

Given that mobile digital imaging analyses (DIA) are equipped to automate body composition and subsequently alter one's appearance at a given objective body fat percent (BF%), the purpose of this study was to validate the use of this tool for assessments of body image. Participants (f = 134, m = 89) from two separate centers underwent body composition scans using a mobile DIA and completed the Multidimensional Body Self-Relations Questionnaire-Appearance Scale (MBSRQ-AS). Using a DIA-generated avatar, participants altered their figure so that it represented their perceived body, ideal body, and what a partner would find attractive. Distortion was calculated as perceived minus actual BF% and dissatisfaction was calculated as either ideal or partner minus perceived BF%. The total sample and females (p < 0.050), but not males, had significantly lower perceived BF% compared to their actual. Ideal and partner BF% was significantly lower than the perceived BF% for all groups (all p < 0.050). Ideal and partner BF% mean differences (MD) from perceived were positively associated with appearance evaluation (AE) and body area satisfaction (BAS) and negatively associated with overweight preoccupation and self-classified weight for the total sample (all p < 0.050). PerceivedMD demonstrated negative associations with AE and BAS (p < 0.050), but only for females when separated by sex. Perceptual body image measured by DIA is significantly associated with attitudinal body image and may allow practitioners to better quantify this growing issue.

Industry progress report on neuro-oncology: Biotech update 2013.

For the second time, The Brain Tumor Center of the Weill Cornell Brain and Spine Center, in collaboration with Voices Against Brain Cancer, hosted The Brain Tumor Biotech Summit in New York City in June 2013. After a very successful first summit in 2012, this innovative event has established a platform for intensive networking between neuro-oncologists, neurosurgeons, neuroscientists, members of the biotechnology and pharmaceutical communities, members of the financial community and leaders of non-profit organizations. This year's summit highlighted dendritic cell vaccines, novel antibody, heat shock protein and targeted therapies as well as exosome technologies, MRI-guided therapies and other novel drug delivery tools. This report presents a short overview of the current progress in brain tumor research and therapy as presented at the 2013 Brain Tumor Biotech Summit.

Industry progress report on neuro-oncology: a biotech update.

With steadily rising revenue and large numbers of clinical trials utilizing novel treatment strategies, the field of neuro-oncology is at the core of the growing cancer therapy industry. In June 2012, the Weill Cornell Brain and Tumor Center hosted the first Brain Tumor Biotech Summit as a forum for fostering and encouraging collaboration between researches and investors to accelerate novel treatments for brain cancer. This event brought together neuro-oncologists, neurosurgeons, academicians, entrepreneurs, non-profits, CEOs and investors in an attempt to bring innovative treatments and concepts to the fore. Specific subjects presented at the meeting included new surgical devices and delivery techniques, targeted therapeutics, immunotherapy, and stem cell biology. The mission of the summit was to provide opportunities for researchers in neuro-oncology to directly interact with leaders from the investment community with insight into the commercial aspects of our work. Our shared goal is to shorten the time for basic science ideas to be translated into the clinical setting. The following serves as a progress report on the biotech industry in neuro-oncology, as presented at the Brain Tumor Biotech Summit.